North Estonia Medical Centre Foundation
- Address
- lock Available on a paid plan
Kidney Disease Research
The North Estonia Medical Centre Foundation’s nephrology unit is testing innovative treatments to reduce proteinuria and protect renal function in patients with immunoglobulin A nephropathy and other glomerular disorders.
- Immunoglobulin A nephropathy
- Focal segmental glomerulosclerosis
- Chronic kidney disease
- End‑stage kidney disease on dialysis
- Proteinuria reduction strategies
These studies aim to improve long‑term outcomes for individuals with chronic kidney disease and those receiving dialysis.
Cancer and Hematology Trials
Researchers are evaluating new immunotherapies and targeted agents to extend survival in a range of malignancies, including non‑small cell lung cancer and hematologic cancers.
- Non‑small cell lung cancer
- Gastric and gastroesophageal adenocarcinoma
- Metastatic castration‑resistant prostate cancer
- Acute myeloid leukemia
- Multiple myeloma
- Colorectal cancer
The goal is to assess the efficacy of novel drug combinations and improve disease‑free survival across solid tumors and blood cancers.
Cardiovascular and Metabolic Studies
The centre is conducting trials that explore innovative anticoagulants and lipid‑lowering therapies to lower the risk of major cardiovascular events in high‑risk populations, such as those with atrial fibrillation or elevated genetic risk.
- Atherosclerotic cardiovascular disease
- Atrial fibrillation
- Hypercholesterolemia
- High polygenic risk for coronary artery disease
- LDL‑cholesterol reduction
These investigations seek to demonstrate reductions in heart attacks, strokes, and cardiovascular mortality.
Autoimmune and Inflammatory Disorders
Ongoing studies focus on biologic and small‑molecule agents designed to control inflammation in conditions such as psoriatic arthritis and inflammatory bowel disease.
- Psoriatic arthritis
- Rheumatoid arthritis
- Moderate to severe ulcerative colitis
- Crohn's disease
- Plaque psoriasis
The purpose of these trials is to achieve better symptom control, reduce disease flares, and improve patients’ quality of life.
Infectious and Respiratory Disease Research
The site is evaluating new antimicrobial and antifibrotic compounds to treat serious infections and progressive lung diseases, including complicated urinary tract infections and fibrotic interstitial lung disorders.
- Complicated urinary tract infection
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- Progressive fibrosing interstitial lung disease
- Pulmonary emphysema due to Alpha‑1 antitrypsin deficiency
These trials aim to improve infection cure rates and slow lung function decline in affected patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 18 therapeutic areas and 15 of 172 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 171 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1Boehringer Ingelheim Espana S.A.3active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC11trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in North Estonia Medical Centre Foundation
lock Showing 1 of 90 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 172 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 10 | Unknown | 2015-11-06 | 2025-02-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.